Rosetta Grants Prometheus Rights to Sell Suite of microRNA Diagnostics in US | GenomeWeb

This story has been updated to include comments from Rosetta's president and CEO.

Rosetta Genomics
this week announced that it has granted the right to market and sell its three microRNA-based diagnostics in the US to drug and diagnostic firm Prometheus Laboratories.

The deal is the latest move by Rosetta to find commercialization partners for its existing products as it shifts its focus onto non-invasive tests designed to screen for, rather than diagnose, disease.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.